# Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)

> **NCT00305461** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 101 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Ciclesonide

## Key facts

- **NCT ID:** NCT00305461
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-03
- **Final completion:** 2008-02
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2016-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305461, "Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00305461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*